\-\ Texto\\:\\ \ \(0\)\
\-\ serum\\ gastrin\\ \\>1000\ \(0\)\
\-\ abnormally\\ increased\\ uptake\\ is\\ present\\ anterior\\ to\\ the\\ right\\ kidney\\ in\\ the\\ region\\ of\\ the\\ head\\ of\\ the\\ pancreas\\,\\ consistent\\ with\\ gastrinoma\\.\ \(0\)\
\-\ symptomatic\\ gastrinoma\\,\\ diagnosed\\ by\\ labaratory\\ and\\ octreoscan\\.\ \(0\)\
\-\ metastatic\\ neuroendocrine\\ tumor\\.\\ \\ gastrinoma\\ is\\ the\\ likely\\ etiology\\,\\ given\\ symptomatology\\,\\ abnormally\\ elevated\\ gastrin\\ levels\\,\\ and\\ the\\ location\\ of\\ the\\ primary\\ lesion\\.\\ \\ other\\ neuroendocrine\\ tumors\\ that\\ demonstrate\\ abnormally\\ increased\\ uptake\\ on\\ octreoscan\\ include\\ carcinoid\\,\\ pheochromocytoma\\,\\ neuroblastoma\\,\\ paraganglioma\\,\\ insulinoma\\,\\ vipoma\\,\\ medullary\\ thyroid\\ carcinoma\\,\\ etc\\.\ \(0\)\
\-\ chronic\\ nausea\\ and\\ vomitting\\ with\\ abnormally\\ high\\ serum\\ gastrin\\ levels\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gastrin\\:\\ 0\\.21638516687902742\ \(0\)\
\-\ gastrinoma\\:\\ 0\\.20457550353607115\ \(0\)\
\-\ abnormally\\:\\ 0\\.18270464309876452\ \(0\)\
\-\ octreoscan\\:\\ 0\\.15771594647391363\ \(0\)\
\-\ neuroendocrine\\:\\ 0\\.1264647248732515\ \(0\)\
\-\ labaratory\\:\\ 0\\.08558755751423784\ \(0\)\
\-\ serum\\:\\ 0\\.08008098139295834\ \(0\)\
\-\ vipoma\\:\\ 0\\.07885797323695681\ \(0\)\
\-\ insulinoma\\:\\ 0\\.06996194671390676\ \(0\)\
\-\ levels\\:\\ 0\\.06849031831596045\ \(0\)\
\-\ uptake\\:\\ 0\\.06592200824648956\ \(0\)\
\-\ vomitting\\:\\ 0\\.06323236243662575\ \(0\)\
\-\ 1000\\:\\ 0\\.059295807988973666\ \(0\)\
\-\ symptomatology\\:\\ 0\\.05358914133943853\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.05358914133943853\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.05135104756650812\ \(0\)\
\-\ carcinoid\\:\\ 0\\.04929950296779737\ \(0\)\
\-\ etc\\:\\ 0\\.04491129788291332\ \(0\)\
\-\ pancreas\\:\\ 0\\.04245502104345807\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.041477899433946544\ \(0\)\
\-\ increased\\:\\ 0\\.04059193751067292\ \(0\)\
\-\ medullary\\:\\ 0\\.03986396332673946\ \(0\)\
\-\ etiology\\:\\ 0\\.035116712550491966\ \(0\)\
\-\ thyroid\\:\\ 0\\.034003033445870974\ \(0\)\
\-\ nausea\\:\\ 0\\.03340038850759546\ \(0\)\
\-\ symptomatic\\:\\ 0\\.03296100412324478\ \(0\)\
\-\ \\,\\:\\ 0\\.03153903675929562\ \(0\)\
\-\ tumors\\:\\ 0\\.031162294734665055\ \(0\)\
\-\ diagnosed\\:\\ 0\\.030506749095097138\ \(0\)\
\-\ kidney\\:\\ 0\\.029227023835436985\ \(0\)\
\-\ location\\:\\ 0\\.028938909581591194\ \(0\)\
\-\ given\\:\\ 0\\.028440916432197497\ \(0\)\
\-\ elevated\\:\\ 0\\.028148702537466628\ \(0\)\
\-\ \\>\\:\\ 0\\.027564733152121983\ \(0\)\
\-\ primary\\:\\ 0\\.02457654624170579\ \(0\)\
\-\ head\\:\\ 0\\.023530109811397047\ \(0\)\
\-\ carcinoma\\:\\ 0\\.02351386087394045\ \(0\)\
\-\ region\\:\\ 0\\.023433021623682646\ \(0\)\
\-\ likely\\:\\ 0\\.023400873455685985\ \(0\)\
\-\ chronic\\:\\ 0\\.0233688313874466\ \(0\)\
\-\ include\\:\\ 0\\.0232733348352455\ \(0\)\
\-\ high\\:\\ 0\\.02270433069006617\ \(0\)\
\-\ anterior\\:\\ 0\\.0213669206190557\ \(0\)\
\-\ metastatic\\:\\ 0\\.02088455731666107\ \(0\)\
\-\ consistent\\:\\ 0\\.020342701639137893\ \(0\)\
\-\ tumor\\:\\ 0\\.019342061180687486\ \(0\)\
\-\ other\\:\\ 0\\.019122704356334452\ \(0\)\
\-\ demonstrate\\:\\ 0\\.019091768362456706\ \(0\)\
\-\ present\\:\\ 0\\.01873794906729787\ \(0\)\
\-\ lesion\\:\\ 0\\.016898594427188877\ \(0\)\
\-\ that\\:\\ 0\\.014329909986007992\ \(0\)\
\-\ by\\:\\ 0\\.013814280614027908\ \(0\)\
\-\ is\\:\\ 0\\.010918267541450982\ \(0\)\
\-\ the\\:\\ 0\\.00939558245558622\ \(0\)\
\-\ right\\:\\ 0\\.008753705913693365\ \(0\)\
\-\ on\\:\\ 0\\.007028068081217748\ \(0\)\
\-\ and\\:\\ 0\\.005242980749482091\ \(0\)\
\-\ to\\:\\ 0\\.004146292314980449\ \(0\)\
\-\ in\\:\\ 0\\.0040912352440801445\ \(0\)\
\-\ of\\:\\ 0\\.0033933145863491777\ \(0\)\
\-\ with\\:\\ 0\\.002271925749318247\ \(0\)\
\-\ \\.\\:\\ 0\\.002067934141592987\ \(0\)\
